Lannett announced that the Food and Drug Administration (FDA) has approved its Abbreviated New Drug Application (ANDA) for Sumatriptan Nasal Spray, the generic version of GlaxoSmithKline‘s Imitrex Nasal Spray.
Sumatriptan Nasal Spray is a selective 5-HT1B/1D receptor agonist indicated for the acute treatment of migraine. It presumably exerts its therapeutic effects in the treatment of migraine headache through agonist effects at the 5-HT1B/1D receptors on intracranial blood vessels and sensory nerves of the trigeminal system, which result in cranial vessel constriction and inhibition of pro-inflammatory neuropeptide release.
Sumatriptan Nasal Spray will be available as 5mg/spray and 20mg/spray strengths. It is expected to be available in the next several months.
For more information visit Lannett.com.